Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Amerant Bancorp Inc is a banks-regional business based in the US. Amerant Bancorp shares (AMTB) are listed on the NASDAQ and all prices are listed in US Dollars. Amerant Bancorp employs 713 staff and has a trailing 12-month revenue of around USD$174.5 million.
|52-week range||USD$9.01 - USD$19.82|
|50-day moving average||USD$18.1814|
|200-day moving average||USD$14.8481|
|Wall St. target price||USD$18.75|
|Dividend yield||USD$0.94 (4.96%)|
|Earnings per share (TTM)||USD$0.078|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Amerant Bancorp stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amerant Bancorp's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amerant Bancorp's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 183x. In other words, Amerant Bancorp shares trade at around 183x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||USD$174.5 million|
|Operating margin TTM||6.53%|
|Gross profit TTM||USD$174.5 million|
|Return on assets TTM||-0.02%|
|Return on equity TTM||-0.21%|
|Market capitalisation||USD$688.2 million|
TTM: trailing 12 months
There are currently 225,486 Amerant Bancorp shares held short by investors – that's known as Amerant Bancorp's "short interest". This figure is 9.6% down from 249,477 last month.
There are a few different ways that this level of interest in shorting Amerant Bancorp shares can be evaluated.
Amerant Bancorp's "short interest ratio" (SIR) is the quantity of Amerant Bancorp shares currently shorted divided by the average quantity of Amerant Bancorp shares traded daily (recently around 97192.24137931). Amerant Bancorp's SIR currently stands at 2.32. In other words for every 100,000 Amerant Bancorp shares traded daily on the market, roughly 2320 shares are currently held short.
However Amerant Bancorp's short interest can also be evaluated against the total number of Amerant Bancorp shares, or, against the total number of tradable Amerant Bancorp shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amerant Bancorp's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Amerant Bancorp shares in existence, roughly 10 shares are currently held short) or 0.0111% of the tradable shares (for every 100,000 tradable Amerant Bancorp shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amerant Bancorp.
Find out more about how you can short Amerant Bancorp stock.
We're not expecting Amerant Bancorp to pay a dividend over the next 12 months.
Amerant Bancorp's shares were split on a 1:3 basis on 23 October 2018. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amerant Bancorp shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Amerant Bancorp shares which in turn could have impacted Amerant Bancorp's share price.
Over the last 12 months, Amerant Bancorp's shares have ranged in value from as little as $9.01 up to $19.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amerant Bancorp's is 1.4208. This would suggest that Amerant Bancorp's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Amerant Bancorp Inc. operates as the bank holding company for Amerant Bank, N. A. that provides banking products and services to individuals and businesses in the United States and internationally. The company offers a range of checking and savings accounts, certificates of deposit, and money market accounts. It also provides variable and fixed rate commercial real estate loans; loans secured by owner-occupied properties; loans to domestic and foreign individuals primarily secured by personal residence; working capital loans, asset-based lending, participations in shared national credits, purchased receivables, and small business administration loans; loans to financial institutions and acceptances; and consumer loans and overdrafts, such as automobile loans, personal loans, or loans secured by cash or securities and revolving credit card agreements. In addition, the company offers trust and estate planning products and services to high net worth customers, brokerage and investment advisory services in global capital markets, and wealth management and fiduciary services.
Everything we know about the Vaccitech IPO, plus information on how to buy in.
Everything we know about the Artiva Biotherapeutics IPO, plus information on how to buy in.
Everything we know about the Five Star Bancorp IPO, plus information on how to buy in.
Everything we know about the Twin Vee PowerCats IPO, plus information on how to buy in.
Everything we know about the Werewolf Therapeutics IPO, plus information on how to buy in.
Everything we know about the Onion Global Limited IPO, plus information on how to buy in.
Everything we know about the Orbsat Corp IPO, plus information on how to buy in.
Everything we know about the Splash Beverage Group IPO, plus information on how to buy in.
Everything we know about the Privia Health Group IPO, plus information on how to buy in.
Everything we know about the Bowman Consulting Group Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.